Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone
| Autor: | Javier López-Araujo, Rojymon Jacob, Caleb Dulaney, John D. Christein, James Posey, Martin J. Heslin, Kimberly S. Keene, T. E. Wood, Andrew M. McDonald |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.medical_treatment Adenocarcinoma Deoxycytidine Capecitabine Pancreatic cancer Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Neoplasm Invasiveness Treatment Failure Lymph node Aged Neoplasm Staging Retrospective Studies Chemotherapy business.industry Gastroenterology Middle Aged medicine.disease Combined Modality Therapy Gemcitabine Surgery Pancreatic Neoplasms Survival Rate Radiation therapy medicine.anatomical_structure Chemotherapy Adjuvant Female Radiotherapy Adjuvant Fluorouracil Lymph Nodes Neoplasm Grading Neoplasm Recurrence Local business Follow-Up Studies medicine.drug |
| Zdroj: | Journal of Gastrointestinal Cancer. 46:149-155 |
| ISSN: | 1941-6636 1941-6628 |
| DOI: | 10.1007/s12029-015-9702-7 |
| Popis: | The purpose of this study was to investigate the effect of radiotherapy on local control and mordibity for patients with resected lymph node-positive pancreatic cancer as compared to gemcitabine-based chemotherapy alone. Sixty-nine patients received adjuvant therapy for pancreatic adenocarcinoma with lymph node involvement after surgical resection and met the inclusion criteria for this analysis. Forty (58 %) patients received postoperative radiotherapy (PORT) to a median dose of 50.4 Gy with capecitabine or 5-fluorouracil concurrently in all but one case; 15 patients also received gemcitabine prior to PORT. Twenty-nine (42 %) patients received gemcitabine-based chemotherapy without PORT for a median of 6 cycles. The median overall survival for patients receiving PORT was 24.4 months compared to 25.6 months for patients not receiving PORT (p = 0.943). At 2 years, the rate of local control was 57 % for patients receiving PORT compared to 37 % for those who did not (p = 0.034). At 2 years, the rate of palliative local interventions was 16 % for patients receiving PORT compared to 18 % for patients who did not (p = 0.821). The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma. The rates of overall survival and palliative interventions did not differ between the two groups. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink